You are here : Home > Funding & TTO > Europe > Research & Innovation Actions ... > AIMS-2-TRIAL

Europe | European & international partnerships | Brain | Diseases

Autism Innovative Medicine Studies – 2 – Trials


AIMS-2-TRIALS, a continuation of the EU-AIMS project and the first European network of clinical trials for autism, aims to improve and personalize treatments for people with Autism Spectrum Disorders (precision medicine).

european funding : ria (Research and Innovation Actions)

Innovative Medicines Initiative 

Call H2020-JTI-IMI2-2016-10-two-stage (Innovative MEDICINES INITIATIVE - IMI)

Published on 3 July 2018


Autism spectrum disorders (ASD) affect around 1 % of the population and are characterised by difficulties in social interactions and communication as well as repetitive behaviours. The precise symptoms and their severity vary widely from one person to another; some are only mildly afflicted and can lead relatively independent lives, while others are severely disabled and require a lot of specialist care. People with ASD often have other conditions, including epilepsy, depression, anxiety and attention deficit hyperactivity disorder (ADHD). Today, there are no drugs designed specifically to treat ASD; instead, those affected are treated with medicines designed for other conditions.

By creating the first European clinical trial network for autism, AIMS-2-TRIALS aims to improve and personalize treatments for people with ASD (precision medicine). It will do this by creating a pipeline for the development, testing and implementation of new treatments with stakeholder involvement at every stage. The project will establish a global network of clinical trials to validate biological markers and endpoints and reliably show whether a treatment is effective and appropriate. As part of this project coordinated by King's College, the CEA team will conduct genetic imaging studies.

AIMS-2-TRIAL is a continuation of the EU-AIMS project (2012-2018).

Project duration
5 years
55 millions €

​Number of partners

Starting date
June 01, 2018

COORDINATOR : King's College London

Joliot Institute Contact: Vincent Frouin (

website :

H2020 agreement id: 777394


IMI is the world's largest public-private partnership (PPP) in the life sciences. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).

The objective of IMI, particularly in its second phase (IMI2, 2014-2020), is to develop new generation vaccines, drugs and treatments, such as new antibiotics.

For more information: